This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Enoxaparin Versus Unfractionated Heparin in PCI

This study has been completed.
Information provided by:
Triemli Hospital Identifier:
First received: February 23, 2007
Last updated: NA
Last verified: February 2007
History: No changes posted
Enoxaparin 0.75mg/kg BW is not inferior to weight adjusted unfractionated heparin as anticoagulation for PCI

Condition Intervention Phase
Coronary Artery Disease Drug: Enoxaparin i.v. Drug: unfractionated heparin Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Enoxaparin Versus Unfractionated Heparin in PCI

Resource links provided by NLM:

Further study details as provided by Triemli Hospital:

Primary Outcome Measures:
  • Quadruple endpoint: death, MI, urgent TVR, major bleeding

Secondary Outcome Measures:
  • major bleeding, minor bleeding, thrombocytopenia

Estimated Enrollment: 2100
Study Start Date: September 2003
Estimated Study Completion Date: February 2006

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • PCI for stable ischemia or ACS

Exclusion Criteria:

  • Cardiogenic shock,
  • Pretreatment with study drugs,
  • Lack of informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00439855

Division of Cardiology Triemli Hospital Zurich
Zurich, Switzerland, 8063
Sponsors and Collaborators
Triemli Hospital
Principal Investigator: osmund bertel, MD Division of Cardiology Triemli Hospital Zurich
  More Information Identifier: NCT00439855     History of Changes
Other Study ID Numbers: ZEUS
Study First Received: February 23, 2007
Last Updated: February 23, 2007

Keywords provided by Triemli Hospital:
Enoxaparin, heparin, hemorrhages

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Calcium heparin
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action processed this record on June 23, 2017